The 1 analysts offering 12-month price forecasts for Sonnet Biotherapeutics Holdings Inc have a median target of 22.00, with a high estimate of 22.00 and a low estimate of 22.00. The median estimate represents a +2,056.86% increase from the last price of 1.02.
The current consensus among 1 polled investment analysts is to Buy stock in Sonnet Biotherapeutics Holdings Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.51
Reporting Date Nov 30
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.